SOURCE: Chembio Diagnostic Systems, Inc.

Chembio Diagnostic Systems, Inc.

April 17, 2012 12:30 ET

Chembio Diagnostic Systems, Inc. to Present at Taglich Brothers 9th Annual Small Cap Equity Conference

NEW YORK, NY--(Marketwire - Apr 17, 2012) - Taglich Brothers, Inc. is pleased to announce that Lawrence A. Siebert, President & CEO of Chembio Diagnostic Systems, Inc. (OTCQB: CEMI) (PINKSHEETS: CEMI) will be presenting at our 9th Annual Small Cap Equity Conference May 1, 2012. The Conference will take place at the New York Athletic Club, New York City. To request additional information or to register, contact Taglich Brothers at 212-779-2971 or visit www.taglich.com.

About Taglich Brothers

Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

About Chembio Diagnostic Systems, Inc.

Chembio Diagnostic Systems, Inc. (OTCQB: CEMI) (PINKSHEETS: CEMI) develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases. Chembio's patented Dual Path Platform (DPP®) POC technology enables development of POC assays that provide unique features and capabilities such as multiplexing and improved control of challenging sample types, such as oral fluid. An oral fluid HIV test is anticipated to be submitted to and reviewed by the FDA in 2012. Several other tests have also been developed on DPP® and revenues in this product line are expected to grow significantly in 2012. Chembio has been profitable since 2009 and anticipates continued revenue growth and profitability in 2012.

Contact Information

  • Contact:
    Taglich Brothers
    Karen Payne
    Symposia Events
    212-779-2971